US 9850229

I'll verify the patent against live sources while relying on the authoritative full text provided.

US 9,850,229 B2 — Analyst Summary

Sourcing note (important): The authoritative full text you supplied covers the front matter, abstract, and specification of US 9,850,229 B2, but the fetched text is truncated at the "BRIEF DESCRIPTION OF THE DRAWINGS" section and does not include the granted claims. Claim language below therefore comes from a secondary database (DrugPatentWatch, updated June 11, 2026) plus the Google Patents claim/concept index. I flag every place where I am inferring rather than quoting.

1. Bibliographic identification

2. Abstract (verbatim)

"The invention provides a novel class of compounds, pharmaceutical compositions comprising such compounds and methods of using such compounds to treat or prevent diseases or disorders associated with abnormal or deregulated kinase activity, particularly diseases or disorders that involve abnormal activation of B-Raf."

3. Plain-language overview of the claims

Independent claims — what I can confirm: Based on the DrugPatentWatch claim listing, claim 1 appears to be the sole independent claim, and it is a method-of-use claim rather than a compound claim:

• Claim 1 — A method of treating melanoma in a subject, comprising: (a) detecting a mutant BRAF kinase in the melanoma; and (b) orally administering a therapeutically effective amount of (i) a pharmaceutical composition comprising methyl N-[(2S)-1-({4-[3-(5-chloro-2-fluoro-3-methanesulfonamidophenyl)-1-(propan-2-yl)-1H-pyrazol-4-yl]pyrimidin-2-yl}amino)propan-2-yl]carbamate (i.e., the compound the specification calls "compound 9," known as encorafenib / LGX818; CAS 1269440-17-6) or a pharmaceutically acceptable salt thereof, and (ii) a pharmaceutical composition comprising a MEK inhibitor.
  • In plain terms: treat a BRAF-mutant melanoma by giving the patient oral encorafenib together with an oral MEK inhibitor.
• Claim 2 (dependent) — Requires the two compositions to be administered as a non-fixed combination (separate dosage forms, not a single fixed-dose pill).
• Claim 3 (dependent on 2) — Requires sequential administration.
• Claims 10–12, 15–17, 18–20 (as reflected in the database) follow a parallel pattern of narrowing the MEK inhibitor to a named list — AS703026; MSC1936369B; GSK1120212; AZD6244; PD-0325901; ARRY-438162; RDEA119; GDC0941; GDC0973; TAK-733; RO5126766; and XL-518 — and then to ARRY-438162 (selumetinib) at claims 12, 17 and 20. Note: these lists match the MEK-inhibitor list in the specification's combination section.

Claim-set size / composition claims — uncertainty. Google Patents' claim-concept index for this patent shows "MEK inhibitor" tied to 21 claims, "pharmaceutically acceptable salts" to 38 claims, "pharmaceutical composition" to 19, and "melanoma" to 11, and DrugPatentWatch classifies the patent's claim types as "Use; Composition." That is consistent with a claim set of roughly 38 claims containing both method-of-use and composition claims. However, I could not retrieve the full claims verbatim, so I cannot confirm the number of independent claims, whether a composition/compound independent claim exists, or the exact wording of the composition claims. Do not treat the "38 claims" figure as verified.

4. Technical subject matter (from the specification, which is authoritative here)

• Formula I: a pyrazol-4-yl–pyrimidin-2-yl core bearing an aryl/sulfonamide ring; R⁴ is —R⁹ or —NR¹⁰R¹¹, R⁷ is H/C₁₋₄alkyl/C₃₋₅cycloalkyl, Y is N or CR⁶, with a proviso excluding certain R⁵-fluoro / R³,R⁶ both-hydrogen combinations.
• Mechanism/utility: B-Raf (including V600E) inhibition; listed cancers include metastatic melanoma, solid tumors, GBM, AML, prostate, gastric, papillary thyroid, ovarian low-grade carcinoma, colorectal, lung.
• The "compound 9" clinical candidate is encorafenib (LGX818), C₂₂H₂₇ClFN₇O₄S.
• Combination rationale (§ "Raf plus MEK inhibitor combination"): the specification describes MEK-inhibitor reversal of Raf-inhibitor-induced pMEK/pERK signaling, cell growth and transformation (FIG. 1, SW620 CellTiter-Glo data), and states that "a Raf plus MEK inhibitor combination represents a superior treatment strategy." That passage is the technical basis for the combination method claims.
• Data reported: IC₅₀ < 500/250/100/50 nM for V600E B-Raf (AlphaScreen pMEK assay); A375 proliferation IC₅₀ 2 nM for compound 9 vs 76 nM for compound 29; oral AUC ≈ 30 ± 4 µM·hr at 10 mg/kg for compound 9.

5. Litigation / docket check (as of April 26, 2026)

No Federal Circuit appeal docket specifically for US 9,850,229 surfaced in my searches (a CAFC/2026 search returned only unrelated matters, e.g., a Fourth Circuit Sandoz–Amgen etanercept antitrust appeal). I did not query PACER/CAFC's docket system directly, so absence of a 2026 CAFC entry is not proof that none exists.

District court activity (D. Del., all § 271 / ANDA-type patent-infringement suits):

Patents asserted alongside 9,850,229 in the Teva case: 10,005,761; 9,314,464; 9,562,016; 9,598,376; 9,980,944.

Sources: https://www.drugpatentwatch.com/p/alphasignals/litigation/patent/9850229 ; https://www.drugpatentwatch.com/p/alphasignals/litigation/casename/index.php?query=Array+BioPharma+Inc.+v.+Teva+Pharmaceuticals%2C+Inc.%7C1%3A23-cv-00625 ; https://portal.unifiedpatents.com/litigation/Delaware%20District%20Court/case/1%3A22-cv-01316 ; https://portal.unifiedpatents.com/litigation/Delaware%20District%20Court/case/1%3A22-cv-01277

6. FDA linkage

DrugPatentWatch lists US 9,850,229 in two NDAs: BRAFTOVI (encorafenib, NDA 210496-001, approved 2018-06-27, use code: "indicated in combination with binimetinib for the treatment of melanoma with a BRAF mutation") and MEKTOVI (binimetinib, NDA 210498-001, approved 2018-06-27, use code: "indicated in combination with encorafenib for the treatment of melanoma with a BRAF mutation"). That dual listing is consistent with claim 1 reciting both an encorafenib composition and a MEK-inhibitor composition. A GreyB/Pharsight table lists the same patent under binimetinib only (expiry Aug 27, 2030), which appears to be an incomplete listing rather than a conflict.

7. Explicit uncertainties

1. Claim text is from a secondary source. The authoritative text you supplied omits the claims; I could not retrieve the granted claims verbatim from USPTO PatentCenter or the Google Patents claims section. Claim 1/2 wording should be verified against the face of the patent before being relied on.
2. Claim count and independent-claim structure unverified. The concept index hints at ~38 claims including composition claims, but I cannot confirm this or describe those composition claims.
3. Reissue linkage unconfirmed. RE49,556 shares title, all eight inventors and the assignee, and post-dates '229 — but I did not confirm it is a reissue of 9,850,229.
4. Party naming for 1:22-cv-01316 is inconsistent across sources (Google Patents leaves it unnamed; DrugPatentWatch pages associate the docket with Sandoz on one page and with Alembic on another).
5. No 2026 CAFC docket confirmed for this patent; my searches did not hit the appellate docket system directly.

I'll research litigation involving US patent 9850229 using the sources you've specified.

Let me get more detail on the specific Delaware cases and check the litigation databases directly.

Litigation Involving U.S. Patent No. 9,850,229

Short answer: Yes — U.S. Patent No. 9,850,229 (the "’229 patent") has been asserted in Hatch‑Waxman ANDA litigation in the U.S. District Court for the District of Delaware. Both known cases arose from generic manufacturers' Paragraph IV challenges to Array BioPharma's MEK‑inhibitor product (binimetinib/Mektovi). I found two district‑court matters naming the ’229 patent; I found no IPR/PGR at the PTAB and no Federal Circuit appeal specific to the ’229 patent.

Cases

Patents-in-suit (both cases): US 9,314,464; US 9,850,229; US 10,005,761; US 9,562,016; US 9,598,376; US 9,980,944. The court grouped these as the "Huang Patents" (’464, ’229, ’761) and the "Krell Patents" (’016, ’376, ’944).

Case details

1. Array BioPharma Inc. v. Sandoz Inc., 1:22‑cv‑01316‑GBW (D. Del.)

• Cause: 35 U.S.C. § 271 patent infringement (ANDA, Nature of Suit 835). Sandoz counterclaimed and demanded a jury. Corporate parent identified as Novartis AG.
• Filing: Complaint filed Oct. 6, 2022; ANDA notice dated Aug. 24, 2022; 30‑month stay deadline Dec. 27, 2025.
• Counsel: Array — Jack Blumenfeld/Megan Dellinger (Morris, Nichols), Aaron Stiefel, Daniel DiNapoli, David McMullen. Sandoz — Dominick Gattuso (Heyman Enerio), Mark Remus, Laura Lydigsen, Alexis White, Judy He (Crowell & Moring).
• Outcome: Stipulated dismissal without prejudice entered Jan. 9, 2025, pursuant to a private Settlement and License Agreement. The order expressly states it "shall not act as an adjudication on the merits," and does not prohibit Sandoz from maintaining its Paragraph IV certifications or FDA from granting final approval.
• Source: https://www.courtlistener.com/docket/65406191/array-biopharma-inc-v-sandoz-inc/ ; https://dockets.justia.com/docket/delaware/dedce/1:2022cv01316/80275 ; PACER 1:22‑cv‑01316

2. Array BioPharma, Inc. v. Alembic Pharmaceuticals Limited, 1:22‑cv‑01277‑GBW (D. Del.)

• Consolidated with the Sandoz case on Dec. 22, 2022.
• Claim construction (Apr. 16, 2024, D.I. 93): The court construed terms across the six patents, including "simultaneously"/"concurrently" (plain and ordinary meaning; "at the same time") and the "crystallized [binimetinib]" term central to the Krell Patents. The opinion explains the court refers to the ’464, ’229, and ’761 patents as the "Huang Patents."
• Stipulated invalidity (May 28, 2024, D.I. 133/134): A "Joint Stipulated Order Between Array and Sandoz of Invalidity of Certain Claims of U.S. Patent Nos. 9,314,464, 9,850,229, and 10,005,761, and Noninfringement of Certain Claims of U.S. Patent Nos. 9,562,016, 9,598,376, and 9,980,944" was so‑ordered by Judge Williams on May 28, 2024. This means certain claims of the ’229 patent were stipulated invalid (subject to incorporation into final judgment; the parties asked that the stipulated orders be carried into any final judgment rather than entered under Rule 54(b)).
• Thereafter: A proposed pretrial order (D.I. 181, filed May 29, 2025) shows Alembic litigating patent exhaustion and invalidity, with trial scheduled to begin June 17, 2025. Sandoz was dismissed from the consolidated action without prejudice by stipulation (D.I. 165).
• Sources: https://www.courtlistener.com/docket/65382822/93/array-biopharma-inc-v-alembic-pharmaceuticals-limited/ ; https://storage.courtlistener.com/recap/gov.uscourts.ded.80177/gov.uscourts.ded.80177.93.0.pdf ; https://storage.courtlistener.com/recap/gov.uscourts.ded.80177/gov.uscourts.ded.80177.181.0.pdf

Related but NOT involving the ’229 patent

• Array Biopharma Inc. v. Teva Pharmaceuticals, Inc., C.A. No. 23‑625‑GBW (D. Del., filed 2023). In this case Array asserted only the "Crystallized Binimetinib Patents" (US 9,562,016; 9,598,376; 9,980,944) — the ’229 patent was not asserted. Source: https://storage.courtlistener.com/recap/gov.uscourts.ded.82712/gov.uscourts.ded.82712.15.0.pdf

Verification notes and caveats

1. Literal-number check: I confined my search to 9,850,229 / 9850229. Note that the stipulated dismissal order text (as quoted in secondary sources) renders the patent as "9,850, 299" / "9,850,229" in different places; these correspond to the ’229 patent (application 15/179,385). I did not treat any other number (e.g., 9,850,299 as a distinct patent) as a separate case.
2. Ownership context: The ’229 patent's original assignee is Array BioPharma Inc.; Google Patents indicates current assignees include Novartis AG and Array BioPharma Inc. Array later became a Pfizer subsidiary (the Sandoz complaint's Rule 7.1 disclosure identified Pfizer Inc. as parent).
3. Orange Book / IPR: DrugPatentWatch lists the ’229 patent in the Mektovi (binimetinib) Orange Book listing with expiry Aug. 27, 2030 (the ’229 patent also appears with use code U‑2333 in the FDA Orange Book). I found no PTAB IPR/PGR and no Federal Circuit appeal directed specifically at the ’229 patent. Source: https://www.drugpatentwatch.com/p/litigation/patent/index.php?query=9850229
4. Completeness caveat: I relied on CourtListener/RECAP, Justia, DrugPatentWatch, Dockets.Justia, and PACER‑derived records. RECAP coverage of the Alembic case is incomplete, and the ultimate disposition of the June 2025 Alembic trial (and whether any final judgment incorporating the ’229 invalidity stipulation was entered, and/or appealed) is not confirmed in the sources I retrieved. Treat the Alembic outcome as "stipulated invalidity of certain ’229 claims; case proceeded to trial mid‑2025, final disposition unverified" rather than a definitive merits ruling. If you need a docket‑certified final status, a direct PACER pull of 1:22‑cv‑01277‑GBW is advisable.

If you'd like, I can attempt a targeted follow‑up on the Alembic final judgment/appeal status or check for any non‑Delaware or ITC actions.

I'll verify the structured "no PTAB activity" default against live sources before finalizing.

The first search surfaced a serious look-alike risk: several "IPR ... '229 patent" documents in the results are not about this patent. Let me pin that down and check for encorafenib/binimetinib-specific PTAB activity.

The look-alike risk is confirmed: the "IPR "'229 patent"" hits are U.S. 8,138,229 (Abraxis/Celgene, albumin–paclitaxel) — a different patent, owner, and technology. Let me check one more angle before concluding.

Proceedings overview

**There are zero AIA trial proceedings on U.S. Patent No. 9,850,229 — no IPR, no PGR, and no CBM — so there is nothing to break down by status (active: 0 / claims invalidated: 0 / claims sustained: 0 / settled: 0 / institution denied: 0); the defensive posture this gives a defendant is "no PTAB estoppel, no PTAB record, and no free kill-shot," but also no PTAB shield — the ’229 patent's only claim-level losses so far came from a district-court stipulation, not from the Board.

Sourcing. The canonical "PTAB proceedings on file" block supplied in this prompt states that the USPTO Open Data Portal returns no AIA trial proceedings for this patent. My independent web checks are consistent with that: I found no petition, institution decision, FWD, or appeal directed at U.S. 9,850,229. Because there are no proceedings to report, the per-proceeding template below is not applicable; instead I use the space to (a) document the look-alike false positives a searcher will hit, and (b) hand the defendant the claim-level invalidity facts that do exist, from the district court.

No proceedings — but three "229" patents will poison your search

This is the single most important finding for a practitioner researching this patent. Searches for "IPR" + "'229 patent" return a large volume of dense, authoritative-looking PTAB material that belongs to a completely different patent, owner, and technology. None of it is about your patent.

The Abraxis IPRs are real and substantive — e.g., the Board instituted on claims 1–48 of 8,138,229 on 2017-10-10 in IPR2017-01104, and Cipla filed a substantially identical follow-on petition in IPR2018-00164 seeking joinder. A one-click citation check will make you look careless if you misfile it. The Abraxis institution decision is public at Docket Alarm (https://www.docketalarm.com/cases/PTAB/IPR2017-01104/Inter_Partes_Review_of_U.S._Pat._8138229/docs/10-10-2017-Board/Institution_Decision-7-Trial_Instituted_Document.pdf) and the Cipla petition at https://paragraphfour.com/uploads/cases18/ipr18-0164P.pdf — both plainly recite 8,138,229 B2 and "COMPOSITIONS AND METHODS OF DELIVERY OF PHARMACOLOGICAL AGENTS."

I also found no ex parte reexamination (90/xxxxxx) and no PGR/CBM on 9,850,229. Treat that as "none found," not as "none exists," since I could not query the Office's reexam registry directly.

Where the ’229 patent's claims actually stand (district court, not PTAB)

Because there is no PTAB record, the relevant claim-level disposition comes from D. Del. C.A. No. 22-1277-GBW, and it is directly material to any defendant:

Claims of the ’229 patent stipulated INVALID — 8 claims: 5, 6, 11, 12, 16, 17, 19, and 20.

• Basis: indefiniteness under 35 U.S.C. § 112, flowing from the court's 2024-04-16 claim-construction ruling that the term "ARRY-438162" (selumetinib, the then-unapproved code name) is indefinite.
• Mechanism: a joint stipulated order between Array and Alembic, so-ordered 2024-05-28, not a merits trial verdict. It was expressly not entered under Rule 54(b); the parties asked that it be carried into any final judgment, and Array preserved its appellate rights on the construction, reserving the right to supplement infringement contentions on remand.
• Source: https://storage.courtlistener.com/recap/gov.uscourts.ded.80177/gov.uscourts.ded.80177.131.0.pdf

The same ruling knocked out parallel claims in sibling patents: claims 11–13, 18–20, 25–27 of the ’464 patent; claims 12, 13, 15, 18–22 of the ’761 patent.

Critical distinction for a defendant: the invalidated claims are the ones that specifically name ARRY-438162. Claims 1–4 survive — and claim 1 recites the genus "a MEK inhibitor," not a species. So the practical threat profile is:

• Claims 1–4 (generic MEK inhibitor, oral, melanoma + BRAF-mutant detection): not stipulated invalid, still live, still in the Orange Book, expiry 2030-08-27.
• Claims 5, 6, 11, 12, 16, 17, 19, 20 (species/selumetinib-reciting): stipulated invalid — but appealable.
• Remaining asserted claims after the stipulation (per the order's ¶ 6) continue with claims 1–4 and 9–10, among others; the order text as retrieved is truncated mid-list, so treat the full surviving set as unverified.
• The Sandoz-side stipulated order (D.I. 133/134, so-ordered 2024-05-28) covered the same three Huang patents.

Biggest live variable: if the Federal Circuit reverses the "ARRY-438162" indefiniteness construction, the eight ’229 claims spring back to life. I found no Federal Circuit appeal docket on the ’229 patent, and no confirmation of a final judgment or appeal following the June 2025 Alembic trial. This is an information gap, not a negative finding — it should be closed with a direct PACER pull of 1:22-cv-01277-GBW.

Cross-reference flag: the prior sections of this analysis identify RE49,556 (Array BioPharma, same eight inventors, filed 2021-07-15, issued 2023-06-20) as probably a reissue of this patent. A reissue is examined by the Office but is not a PTAB trial proceeding, so it does not appear in the AIA-trial count. If RE49,556 is in fact the ’229 reissue, then the reissue claims — not the original claims — define the enforceability perimeter, and any analysis keyed to the original claim numbers must be re-run against the reissue. Flagging as unconfirmed, consistent with the earlier section.

Strategic summary

None of the ’229 claims have been canceled by the PTAB. There is no Final Written Decision, no Certificate of Cancellation, and therefore no statutorily canceled claims. The claims that are invalid — 5, 6, 11, 12, 16, 17, 19, 20 — were invalidated by district-court stipulation on § 112 indefiniteness grounds, which is a materially weaker durability position for the patent owner than a PTAB cancellation would be in the opposite direction: the stipulated order is not a merits adjudication, is not Rule 54(b)-final, and Array expressly reserved the right to appeal. Everything else — including independent claim 1's generic "a MEK inhibitor" genus — is untested for validity. No adjudicator, PTAB or district court, has passed on whether claims 1–4 are valid.

Estoppel: there is none. Because no IPR was ever instituted against this patent by anyone, 35 U.S.C. § 315(e)(2) does not bar any ground — not for you, not for your co-defendants, not for anyone. There is no IPR estoppel to navigate and no Sotera-type stipulation to worry about. Correlatively, the patent owner gets no PTAB-tested presumption: nothing about this patent has been stress-tested at the Board, so the invalidity record is genuinely open. The prior art you can raise in district court is limited only by § 282 and KSR practice, not by anything § 315(e)(2) would have swept in. Note the array of Orange Book siblings — ’464, ’016, ’376, ’944, ’761, ’050, ’693, ’293 — many of which were asserted (Teva asserted only the crystallized-binimetinib patents), so cross-patent § 315 estoppel from other patents' IPRs, if any, would not reach the ’229.

Pattern signals. All negative, and collectively telling: no petitioner has ever filed on this patent; no serial or follow-on petitions; no defensive aggregator (no Unified Patents or RPX filing appears anywhere in the ’229 chain); no PTAB appeal by Array because there was no adverse Board decision to appeal. The ’229 patent instead went straight to Hatch-Waxman litigation in D. Del. in 2022 and 2023, where the generic challengers attacked via § 112 indefiniteness at claim construction rather than via § 102/§ 103 at the Board — and won a partial, stipulated, non-final, appealable result. That is an unusual posture: well-asserted pharmaceutical patents of this commercial significance (Braftovi/Mektovi, both NDAs) ordinarily attract IPRs. The absence here most plausibly reflects that the ANDA defendants' best path was indefiniteness on a claim term, not art-based invalidity, and that settlement resolved the Sandoz track in 2025 before any Board filing became attractive.

Recommended next steps

If you are a defendant being asserted on this patent:

1. Do not cite IPR2017-01104 or IPR2018-00164 as invalidity of your patent. They are U.S. 8,138,229 (Abraxis/Celgene, albumin–paclitaxel). Filing a notice relying on them would be a self-inflicted credibility wound.
2. Do not assume the eight stipulated-invalid claims are dead for all purposes. They are invalid only via a non-final stipulated order that Array has expressly reserved the right to appeal, and that both parties asked to be folded into a final judgment rather than entered under Rule 54(b). If the Federal Circuit reverses the "ARRY-438162" construction, claims 5, 6, 11, 12, 16, 17, 19, 20 are revived. A design-around built on avoiding only selumetinib (ARRY-438162) language may not clear claims 1–4.
3. Aim your invalidity case at claims 1–4, which recite the generic MEK inhibitor genus and have never been adjudicated by anyone. That is the untested surface. § 315(e)(2) estoppel is a non-issue, so your full § 102/§ 103 arsenal is available.
4. Pull the docket directly. I could not confirm whether a final judgment was entered after the June 2025 Alembic trial, or whether Array appealed the claim construction. PACER 1:22-cv-01277-GBW is the authoritative source. If a final judgment incorporating the stipulation has been entered and appealed, the validity posture changes materially and immediately.
5. Check the reissue. If RE49,556 is confirmed as the reissue of the ’229, analyze its reissue claims — reissue can broaden or narrow, and the enforceability perimeter follows the reissue. Verify the "reissue of 9,850,229" designation on the face of RE49,556 before relying on it.

If you are monitoring rather than defending: the absence of PTAB activity is itself the signal. There is no Board record to mine, no FWD reasoning to borrow, and no petitioner-side expert declaration to reuse. Any invalidity position you build will be built from scratch, in district court, against claims 1–4 that no tribunal has yet construed for validity.

Explicit uncertainty: my conclusion that no AIA trial exists rests on (i) the structured ODP-derived block in this prompt stating no AIA trial proceedings, and (ii) targeted web searches that surfaced only look-alikes. I did not retrieve a PTAB E2E proceeding listing page for 9,850,229 directly, and I did not query the ex parte reexamination registry. Given the density of 8,138,229 and 8,193,229 noise around this number, I recommend a confirmation pull of PTAB E2E / PTAB Center filtered to patent number 9,850,229 (not "229") before any filing that asserts the absence of prior PTAB proceedings.

I'll research the assignment record for US 9,850,229 across the sources specified.

Inventors

All eight named inventors are listed with California addresses on the corresponding EP family member (EP 2 470 526 B1, applicant IRM LLC of Hamilton HM LX, Bermuda, and Novartis AG, Basel), which is the same eight-name set that appears on '229 and in the '229 family's U.S. assignment records:

Employer at time of filing: Novartis. The split is itself informative — six inventors assigned to IRM LLC (a Bermuda Novartis holding entity associated with the Novartis San Diego research operation, the Genomics Institute of the Novartis Research Foundation) and two (Jin and Poon) assigned directly to Novartis AG. That two-track inventor assignment is consistent with two different Novartis employment vehicles, not with an independent lab. Source for the applicant/inventor/address data: https://data.inpi.fr/brevets/EP2470526

Unusual-pattern check — inventor departures: I could not determine departure dates for any inventor; the USPTO assignment index does not carry employment-end data and I found no corroborating source. I can only note the surrounding context: (a) the whole encorafenib program was divested from Novartis to Array in March 2015, and (b) the '229 continuation was filed 2016-06-10 and the assignment chain recorded one month later. I did not find evidence of an inventor exodus preceding a portfolio fire-sale. Call: unclear / not determinable — flagging rather than fabricating.

Original assignee

Array BioPharma, Inc. ("Array"), 3200 Walnut Street, Boulder, CO 80301 — the original assignee named on the issued patent, per Google Patents' front-matter field ("Original Assignee: Array BioPharma Inc.").

• Did they ship a product embodying the claims? Yes, directly. Array is the NDA holder and Orange Book patent owner for BRAFTOVI (encorafenib, NDA 210496-001, approved 2018-06-27) and MEKTOVI (binimetinib, NDA 210498-001, approved 2018-06-27). '229 is delisted/linked against both NDAs; the BRAFTOVI and MEKTOVI use codes are the reciprocal combination-melanoma indications. Sources: https://www.drugpatentwatch.com/p/patent/[9850229](/patent/9850229) ; https://www.drugpatentwatch.com/p/alphasignals/litigation/patent/9850229
• Primary line of business: clinical-stage/ commercial-stage small-molecule drug discovery and development, focused on oncology (kinase inhibitors).
• Current status: Acquired. Pfizer Inc. acquired Array in an all-cash merger completed in July 2019 (announced June 2019, ~$11.4B). Array BioPharma, Inc. survives as a wholly-owned Pfizer subsidiary; the Orange Book and court filings still name "Array Biopharma Inc" as NDA holder/plaintiff. Novartis AG appears in Google Patents' assignee field only as a residue of the recorded chain (see timeline) — the last recorded link runs from Novartis AG to Array, and no later Array→Pfizer patent assignment is recorded (stock mergers generally are not recorded as patent assignments).

Cross-reference flag (contradiction): the earlier Patent summary §5 listed 9,850,229 among patents "asserted alongside … in the Teva case," whereas the earlier Litigation summary states the Teva case (1:23-cv-00625) asserted only the crystallized-binimetinib patents and that '229 was not asserted there. The litigation-specific finding (with a CourtListener RECAP citation) is the better-supported one. The Patent summary also listed a 1:25-cv-01016 Alembic case that does not appear in the litigation section. Both affect assertion history, not the ownership chain below.

Assignment timeline

Important sourcing limitation, stated up front: the USPTO Assignment Center / Assignment Search records for US 9,850,229 exist and are reflected in Google Patents' legal-events panel for this patent (five conveyances, all recorded 2016-07-13). However, I was unable to retrieve the individual reel/frame numbers or the correspondent-of-record entries for these five records from the sources available to me, and I will not invent reel/frame numbers or attorneys. The entries below give everything I can substantiate; fields I could not verify are marked [not retrieved].

The authoritative full text you supplied (Google Patents legal events for US9850229B2) shows five recorded conveyances, all bearing the recording/effective date 2016-07-13:

• Executed date [not retrieved] / recorded 2016-07-13 — Reel [not retrieved]

  • Conveyance: Assignment of Assignors Interest
  • Assignor: Huang, Shenlin; Liu, Zuosheng; Wang, Xing; Xie, Yongping; Wan, Yongqin; Tellew, John (six of the eight inventors)
  • Assignee: IRM LLC (Hamilton HM LX, Bermuda)
  • Correspondent: [not retrieved]
  • Context: Original inventor-to-employer assignment, Novartis-side. Executed around the 2009–2010 priority filings but re-recorded against this 2016 continuation.

• Executed [not retrieved] / recorded 2016-07-13 — Reel [not retrieved]

  • Conveyance: Assignment of Assignors Interest
  • Assignor: Jin, Xianming; Poon, Daniel (the remaining two inventors)
  • Assignee: Novartis AG (Lichtstrasse 35, 4056 Basel, Switzerland)
  • Correspondent: [not retrieved]
  • Context: Original inventor-to-employer assignment, routed to the Swiss parent rather than IRM LLC.

• Executed 2015-01-05 (per the same merger document recorded elsewhere in the family) / recorded 2016-07-13 — Reel [not retrieved for '229]

  • Conveyance: Merger ("MERGER (SEE DOCUMENT FOR DETAILS)")
  • Assignor: IRM LLC
  • Assignee: Novartis International Pharmaceutical Ltd. (Hamilton, Bermuda)
  • Correspondent: [not retrieved for '229]. On a sibling same-title application (US 16/741,937 → US 2020/0323852), this same merger document was recorded with correspondent Banner & Witcoff, Ltd., 1100 13th Street NW, Suite 1200, Washington, DC 20005 — see https://www.plainsite.org/patents/assignment.html?id=[10030751](/patent/10030751). Flag: Banner & Witcoff is Novartis's outside IP firm and a large general-practice prosecution firm with no identified NPE-plaintiff association. The same merger was also recorded as reel 035469/0260 (recorded 2015-04-22) against an unrelated Novartis patent, US 7,563,894 (see Dimensions record for US-7563894-B2). The recurring re-recording of one merger document across newly filed continuations is an administrative artifact, not repeated NPE-style conveyancing.
  • Context: Internal corporate reorganization — Novartis group holding-company merger; no change in ultimate control.

• Executed [not retrieved] / recorded 2016-07-13 — Reel [not retrieved]

  • Conveyance: Assignment of Assignors Interest
  • Assignor: Novartis International Pharmaceutical Ltd.
  • Assignee: Novartis AG (Basel, Switzerland)
  • Correspondent: [not retrieved]
  • Context: Internal reorganization — consolidation of the Novartis-side title into the Swiss parent.

• Executed on/about 2015-03-02 (date inferred from the agreement's Effective Date; not confirmed on the face of the '229 record) / recorded 2016-07-13 — Reel [not retrieved]

  • Conveyance: Assignment of Assignors Interest
  • Assignor: Novartis AG
  • Assignee: Array BioPharma, Inc. (Boulder, CO)
  • Correspondent: [not retrieved]
  • Context: Carve-out divestiture — the substantive instrument is the LGX818 Asset Transfer Agreement between Novartis Pharma AG and Array BioPharma Inc., dated January 19, 2015, effectuated together with the termination/asset-transfer agreement for binimetinib under which Array regained worldwide rights to both assets effective March 2, 2015, with Novartis paying Array $85.0M. This divestiture was a European Commission merger remedy in the GSK/Novartis oncology three-part transaction (EC/FDA order materials: https://www.fdanews.com/ext/resources/files/04-15/04-09-15-GSKNovartisorder.pdf ; agreement text: https://contracts.justia.com/companies/array-biopharma-inc-2092/contract/[442134](/patent/442134)/ ; Array 10-Q disclosure: https://getfilings.com/sec-filings/[151106](/patent/151106)/ARRAY-BIOPHARMA-INC_10-Q/).

Post-chain matters that are not recorded assignments:

• Licenses, not assignments: Array granted commercialization rights to Pierre Fabre Médicament (ex-US/Canada/Japan/Korea/Israel) effective Dec 2015 and to Ono Pharmaceutical (Japan/Korea) effective May 2017. The French register for the EP family member shows a license entry (CL, BOPI 2018-29) to Pierre Fabre — see https://data.inpi.fr/brevets/EP2470526. Licenses are generally not recorded in the USPTO assignment database and none appears in the '229 chain.
• Reissue RE49,556 (filed 2021-07-15, issued 2023-06-20; same eight inventors, assignee Array BioPharma Inc.) — per the earlier Patent summary, a probable reissue of this patent, but that linkage was not confirmed. If it is a reissue, it is a re-grant of the same rights, not an ownership transfer.

Bottom line for this section: there are Assignment Center records — five conveyances, all recorded 2016-07-13 — and the chain they describe is fully reconstruable as to parties and conveyance types. What I could not obtain is the reel/frame and correspondent fields for each of those five records. Verify the exact reel/frame numbers directly at the Assignment Center search page: https://assignmentcenter.uspto.gov/ (patent number search on 9850229).

Timeline diagram

timeline
    title Ownership of US 9850229
    2009 : Priority provisional filed by Novartis inventors
    2010 : Second priority provisional filed
    2015 : IRM LLC merger document executed
         : Novartis divests encorafenib to Array
    2016 : Continuation application filed
         : Five assignments recorded 2016-07-13
    2017 : US 9850229 B2 issues
    2019 : Pfizer acquires Array BioPharma
    2022 : First ANDA suits filed against generics

NPE / troll-pattern signals

1. Shell-entity transfer — Not present. The chain runs inventors → IRM LLC → Novartis International Pharmaceutical Ltd. → Novartis AG → Array BioPharma, Inc. (recorded 2016-07-13 set). Every named entity is a Novartis group company or Array. No "IP / Holdings / Ventures / Licensing" vehicle appears; no registered-agent-only address; no single-purpose Delaware or Texas LLC. IRM LLC's Bermuda address is Novartis's long-standing corporate domicile for that entity, used across dozens of unrelated Novartis patents.

2. Known asserter in the chain — Not present. None of IRM LLC, Novartis International Pharmaceutical Ltd., Novartis AG, or Array BioPharma, Inc. appears on the Acacia / Marathon / Intellectual Ventures / IPNav / Wi-LAN / Conversant / Vringo / Pendrell / Round Rock / Spangenberg or comparable lists. Array asserted the patent in its own name as the Orange Book NDA holder.

3. Repeat correspondent across the chain — Unclear, leaning not present. I could not retrieve the correspondents of record for the five '229 entries [not retrieved]. The only correspondent I could substantiate anywhere in this family is Banner & Witcoff, Ltd. on the sibling-application merger record (PlainSite assignment ID 10030751). That is a large general-practice IP prosecution firm handling Novartis's corporate-reorg recordings; a single recurring firm doing operating-company reorg work is not the NPE tell (the tell requires a repeat NPE-assertion filer). No NPE-linked recording attorney was identified.

4. Cascading transfers — Not present (as an NPE pattern). There are four sequential links, all recorded on the same day (2016-07-13), compressing a 2009–2016 corporate history into one recording batch. The hops are intra-Novartis (merger + consolidation) followed by a single regulatory-mandated divestiture to Array. There is no <24-month daisy-chain of unrelated LLCs, no shared registered-agent address among "unrelated" assignees, and no common-principal shell structure.

5. Pre-litigation transfer — Not present. The last recorded link in the chain bears the recording date 2016-07-13 (underlying agreement executed ~March 2015). The first infringement suits naming '229 were filed 2022-09-28 / 2022-10-06 (D. Del. 1:22-cv-01277 v. Alembic; 1:22-cv-01316 v. Sandoz) — roughly 7.5 years after the transfer, and 4+ years after the 2018 FDA approvals. There is no proximity between the assignment and the filing date. (Cross-reference note: the earlier Patent summary's assertion that '229 was asserted in the 2023 Teva case conflicts with the litigation-specific finding that Teva asserted only the crystallized-binimetinib patents; either way it does not create a pre-litigation-transfer signal.)

6. Bankruptcy fire-sale — Not present. Array was acquired by Pfizer in 2019 in a ~$11.4B all-cash going-concern merger; Array was not in Chapter 7/11 and no patent sale in bankruptcy proceedings occurred. Novartis is a going concern; the Novartis→Array transfer was an antitrust divestiture remedy, which is a regulated forced sale but not a distress sale.

7. Privateering — Not present. The chain ends at an operating company that itself commercializes the claimed subject matter and litigates directly. There is no NPE asserting on Array's or Novartis's behalf; no EFF/Patent Progress/SEC-sourced privateering evidence surfaced.

8. Defensive aggregator (anti-NPE) — Not present. The chain does not terminate at RPX, AST, LOT Network, Unified Patents, or OIN. (Note the Delaware suits are ORANGE-BOOK ANDA actions against generic filers, i.e., the opposite posture from defensive aggregation.)

Verdict

Operating-company assertion.

The recorded chain (all five conveyances recorded 2016-07-13, per the Google Patents legal-events panel for US9850229B2) runs from the eight Novartis-employed inventors → IRM LLC / Novartis AG → Novartis International Pharmaceutical Ltd. → Novartis AG → Array BioPharma, Inc., with no shell LLC, no NPE-list party, and no pre-suit transfer. Array — the original assignee on the face of the patent and the Orange Book NDA holder for BRAFTOVI and MEKTOVI — asserted '229 in its own name against Alembic and Sandoz in D. Del. (2022), and it has since been acquired by Pfizer Inc. as a going-concern subsidiary; none of the eight signals supports an NPE characterization. Verification: search patent 9850229 at the USPTO Assignment Center (https://assignmentcenter.uspto.gov/), and note that the reel/frame and correspondent fields for the five records above remain [not retrieved] in this analysis and should be pulled directly from that source before being cited.

I'll research the prior art citations for US 9,850,229.

Let me dig into the specific citations listed on the patent.

Let me try to retrieve the actual citation list from other patent databases.

Prior-Art Analysis — US 9,850,229 B2

0. Critical sourcing statement (read first)

I could not retrieve the granted patent's "(56) References Cited" list. The Google Patents page for US9850229 truncated at the identical point on every fetch (end of the specification / start of "BRIEF DESCRIPTION OF THE DRAWINGS"), and the authoritative full text you supplied is truncated at the same place. That is precisely the region in which the US patent documents, foreign patent documents and non-patent literature citations are printed on the face of the grant. I also did not obtain a USPTO PatentCenter / Patent Public Search (formerly PAIR) record for 9850229 in this session — my searches surfaced Google Patents, DrugPatentWatch, Unified Patents, GreyB/Pharsight, the HR/LU/EP national registers, and several third-party ISR documents, but not a USPTO-hosted document list.

Consequence: I cannot give you a verbatim, complete list of the citations of record for 9850229. What follows is (a) the closest proxies to that list that I could actually observe, and (b) my own independent prior-art assessment against the granted claims, with every item labelled VERIFIED, HIGH-CONFIDENCE (from recall), or UNVERIFIED. I have not invented document numbers, dates or technical content to fill gaps.

I confined all searches to 9,850,229 / 9850229. Where secondary sources render the number as "9,850,299" (as in the D. Del. stipulated-order text), I treat that as the same patent and flag it rather than auto-correcting it.

1. Verified bibliographic anchor for 9850229

This is VERIFIED via Google Patents, the Croatian State Intellectual Property Office register (HR P20140799 / EP 2470526), and the Luxembourg register (EP 2727918, expiry 27/08/2030, licensee Pierre Fabre Médicament under an "ENCORAFENIB"-restricted licence).

Self-art caution: WO 2011/025927, EP 2,470,526, EP 2,727,918 and the sibling US patents (9,314,464; 9,850,230; 9,593,099; 9,593,100; 10,005,761; 10,568,884; 10,576,080; RE49,556) all share the same eight inventors and the same ownership chain. They are not §102 prior art to 9850229 (common inventive entity and, in any event, the §102(b)(2)(C) common-ownership exception where the AIA applies). They are the priority/§112 context, not the §102 art.

2. The closest observable proxy to the (56) list

2a. Google Patents concept index for US9850229 (VERIFIED as observed)

The concept/links index for 9850229 surfaces, among others:

What this tells us — and what it does not. The encorafenib, BRAF-V600E, melanoma, "MEK inhibitor" and "salts" entries are fully explained by the '229 claims and specification (the encorafenib compound is the claimed active agent; the MEK-inhibitor list in the specification names GDC0973 = cobimetinib). The two named small-molecule structures at the top of the list are not explained by the '229 specification text I hold — neither structure is a pyrazol-4-yl-pyrimidine of Formula I. My working inference is that they entered the index through associated/cited document content rather than through the '229 description, but I could not confirm which document either compound comes from, and I am not asserting they are cited art. Treat both as leads to verify, not as established citations.

2b. A document I did verify as being in the Raf-kinase prior art (not necessarily in the '229 (56) list)

WO 2007/002433 A1 (Plexxikon, Inc. et al.), published 2007-01-04. VERIFIED — I observed it as a cited X-category reference in the KIPO International Search Report for PCT/US2020/019019 (published as WO 2022/105746 A1, search completed 26 June 2020), where it is applied alone against claims 1–18 with the specific passages paragraphs [0007]–[0010], [0331], and "embodiments of the invention." The same ISR lists family member US 2015/0290205 A1 (2015-10-15).

This is the Plexxikon Raf-modulator family (the PLX4720/PLX4032 → vemurafenib lineage). I did not find it expressly listed in the '229's own citation list, because I could not retrieve that list.

3. Independent prior-art assessment against the granted claims of 9850229

3a. The claims I am analysing (flagged as secondary-sourced)

Per the earlier section of this analysis, the granted '229 claims as reflected in secondary databases are method-of-use claims: claim 1 = treating melanoma by (a) detecting mutant BRAF kinase and (b) orally administering encorafenib + a MEK inhibitor; claim 2 = non-fixed combination; claim 3 = sequential; claims 10–12/15–17/18–20 = narrowing the MEK inhibitor to the named list, then to ARRY-438162. This claim text is not verbatim-verified and the approximate ~38-claim structure including composition claims is unverified.

3b. The governing point of law that dominates this analysis

The '229 was filed 2016-06-10 but claims 2009-08-28 priority.

• If the combination method-of-use claims are entitled to the 2009-08-28 (and 2010-03-11) priority dates, pre-AIA §102 governs the original disclosure and the prior-art universe cuts off in August 2009.
• If those claims are not supported by the 2009/2010 provisionals (they recite the combination subject matter that appears in the 2010-filed PCT specification), they take a 2016-06-10 effective filing date, AIA §102(a)(1)/(a)(2) applies, and the prior-art universe expands enormously — it would then include the entire 2010–2016 Raf-inhibitor/MEK-inhibitor combination literature, including the 2010 Nature/NEJM vemurafenib papers and the 2010 "paradox"/feedback papers, and including sibling and third-party publications.
• Hypothesis (clearly labelled as such): the stipulated invalidity of "certain claims" of the '229 entered in D. Del. on 2024-05-28 is consistent with the combination claims being attacked on the later effective filing date. I could not verify which claims were stipulated invalid or on what art.

This priority bifurcation is the single most important variable in any §102 analysis of 9850229, and it cannot be resolved without (i) the granted claims verbatim and (ii) the priority/support record.

3c. Reference-by-reference table

3d. The single most dangerous §102 scenario

A claim-1 anticipation requires one pre-effective-filing-date document disclosing all of: (i) a BRAF inhibitor, (ii) a MEK inhibitor, and (iii) treating BRAF-mutant melanoma with the two in combination — or, more precisely for claim 1 as I understand it, encorafenib together with a MEK inhibitor in BRAF-mutant melanoma.

• Encorafenib's own public disclosure traces to WO 2011/025927 (2011-03-03) — the '229's own family — so no third-party document can anticipate the encorafenib limitation on a 2009-08-28 priority date. That makes plain §102 anticipation of claim 1 unlikely on the early date and pushes the fight onto §103 and onto the priority/§112 question.
• Conversely, if the combination claims are limited to a 2016-06-10 effective filing date, R5 (the 2010 vemurafenib and paradox literature) plus R6-family MEK art becomes available, and the "Raf inhibitor + MEK inhibitor for BRAF-mutant melanoma" combination was squarely in the public domain by 2011–2014. That is where I would expect the invalidity case — and where the 2024-05-28 stipulated invalidity of "certain claims" of the '229 most plausibly sits.

4. What I could not establish (explicit)

1. The (56) references-cited list of US 9,850,229 is not in hand. I could not retrieve it from Google Patents, FreePatentsOnline or USPTO in this session. Every "which claims does it anticipate" mapping in §3c for the cited art is therefore my independent analysis, not a report of the examiner's citations.
2. The granted claim set is not verbatim-verified (it is secondary-sourced, per the earlier section).
3. The origin of the two named compounds in the Google Patents concept index (KKVYYGGCHJGEFJ; VIUAUNHCRHHYNE) is unresolved.
4. The priority/§112 status of the combination claims is unresolved, and it is dispositive of the §102 regime and prior-art cut-off.
5. The stipulated invalidity of "certain claims" of the '229 (D. Del., 2024-05-28) could not be tied to specific claims or specific art.
6. No PTAB IPR/PGR and no Federal Circuit appeal specific to the '229 was found in this session; that is absence of evidence, not evidence of absence.

Recommended next steps to close the gap: (a) pull the printed front page of US 9,850,229 (or the PatentCenter "References Cited" / "Foreign References" / "Other References" tabs) for the verbatim (56) list; (b) pull the file wrapper of 15/179,385 and its parent for the examiner's citations and any priority rejection; (c) pull D.I. 133/134 in D. Del. 1:22-cv-01277-GBW to identify exactly which '229 claims were stipulated invalid and on what art; and (d) obtain RE49,556's file wrapper, since a reissue prosecution often re-litigates the same art.

I'll research the prior-art landscape for US 9,850,229 before building the §103 analysis.

Key lead found: encorafenib is described in WO 2011/025927 and US 8,501,758. Let me dig into the claims, the reissue, and the Raf+MEK combination prior art.

Strong lead: WO 2008/120004 A1 (AstraZeneca) — "Combination of a MEK inhibitor and a B-Raf inhibitor for the treatment of cancer." Let me examine that reference and the reissue claims.

I hit the tool-use cap before I could open three follow-ups, so I'll flag exactly where my sourcing stops and write the analysis from what I verified.

One important sourcing correction up front: you asked me to use the results from the "Prior Art" section of the page. The authoritative full text you supplied for US 9,850,229 is truncated at "BRIEF DESCRIPTION OF THE DRAWINGS" and does not contain the Google Patents Citations / Cited-By / Prior-Art pane at all. It contains only the front-matter line "Prior art keywords: pyrazol; mixture; propan; compound; chloro" and "Prior art date 2009-08-28." So there is no prior-art section to quote. I have therefore assembled the reference set from the closest available substitutes: the search reports and citation tables of the '229 family (EP 2470526 / EP 2727918 / EP 2488033 / KR101729116B9), sibling and downstream patents that recite encorafenib's provenance, the litigation record, and the Orange Book/ANDA correspondence. Every reference below is tagged with how I verified it.

§103 Obviousness Analysis — US 9,850,229 ("the '229 patent")

1. The claim to be analysed

Limitation decomposition — this is what drives the whole analysis:

• (A) Treat melanoma in a subject;
• (B) patient selection: detect a mutant BRAF kinase in the tumour;
• (C) orally administer encorafenib (LGX818; the spec's "compound 9") or a salt;
• (D) orally administer some MEK inhibitor (species-agnostic in claim 1);
• (E) [claim 2 only] the two compositions are a non-fixed combination; [claim 3] sequential dosing; [deps.] the MEK inhibitor is one of a named list of already-known compounds.

Elements (A), (B), (D) and (E) are, on the record, routine; (C) is the only legally contestable element.

2. Governing law and the date problem (this is dispositive, so it comes first)

The '229 patent claims priority to US provisional 61/238,073 (2009-08-28) and 61/313,039 (2010-03-11), via a §120 chain to PCT/US2010/046930, filed 2010-08-27 (the family's EP counterparts EP 2470526 and EP 2727918 both carry the 27.08.2010 filing date — verified in the Latvian SPC register publication for BRAFTOVI/MEKTOVI). The '229 itself was filed 2016-06-10 and the anticipated expiration is 2030-08-27, i.e. twenty years from 2010-08-27. Because every claim carries a pre-2013 effective filing date, pre-AIA §§ 102/103 apply (AIA transition provisions).

Critically, the combination subject matter may not be entitled to the 2009-08-28 date. The specification's combination teaching — FIG. 1 (SW620 CellTiter-Glo; MEK inhibitor "A3" = PD0325901 reversing Raf-inhibitor-induced pERK and cell growth) and the statement that "a Raf plus MEK inhibitor combination represents a superior treatment strategy" — sits alongside the 2010-03-11 provisional in the disclosure. I could not determine from the supplied text whether the Raf + MEK combination disclosure was present in the 2009-08-28 provisional or was added on 2010-03-11 / 2010-08-27. That single fact moves a large block of art in and out of the §102 window, so I analyse both branches.

3. Prior art identified

4. The two-reference combination that renders claims 1–3 obvious

Proposed ground: WO 2008/120004 A1 in view of WO 2009/018238 (Ardea), optionally further in view of the encorafenib-disclosing reference and US 2012/0015973, and further in view of the BRAF-genotyping art (Davies 2002 / routine V600E testing).

Element-by-element:

Why a POSITA would have combined them (the KSR motivation analysis):

1. Express suggestion. WO 2008/120004 A1 is the suggestion: its title and disclosure are the combination of a MEK inhibitor with a B-Raf inhibitor for cancer. This is not an after-the-fact "would have been obvious to try" argument; it is an articulated, published instruction in the same field, one year before the earliest priority date.
2. Mechanistic identity of the targets. BRAF, CRAF, MEK and ERK sit on a single linear pathway. A RAF inhibitor and a MEK inhibitor block the first and second nodes of the same cascade. Blocking two nodes of one pathway is the paradigm of an obvious combination — the art (Montagut 2008) had already taught that RAF inhibition alone is defeated by CRAF/pERK reactivation, which points a POSITA directly at the downstream node as the complementary target. The '229 specification concedes exactly this logic ("the induction of downstream signaling has previously been attributed to published Raf pathway feedback loops").
3. Finite, identified, predictable set of options. The MEK-inhibitor universe was small and enumerated (PD0325901, AZD6244, GSK1120212, ARRY-438162, RDEA119, GDC0973, TAK-733, etc.), several already in Phase I/II. KSR treats a finite number of identified, predictable solutions, with a reasonable expectation of success, as obvious.
4. Reasonable expectation of success, not certainty. Solit 2006 established that BRAF-mutant tumours are MEK-dependent; MEK inhibitors had single-agent activity in BRAF-mutant melanoma. Adding a second agent that hits the same pathway downstream, where the first agent's own resistance mechanism is known to act, is a predictable, "lead-compound-like" optimisation — not an unpredictable leap.
5. No teaching away. The art contains no statement that a RAF + MEK combination is inoperable or counterproductive. Toxicity overlap is not, without more, a teaching away from an efficacy combination — and the '229 specification itself asserts the combination "represents a superior treatment strategy." A patentee cannot simultaneously rely on the combination's superiority as the invention while arguing the art would have expected it to fail.
6. No unexpected-result evidence in the claims. Claim 1 recites no dose, no ratio, no dosing schedule, no PK target and no measured effect. The specification's data (A375 IC₅₀ 2 nM; oral AUC ≈ 30 ± 4 µM·hr at 10 mg/kg) characterise encorafenib, not the combination — so they rebut, at most, obviousness of the compound per se, not of the claimed combination method.

5. The crux: is encorafenib itself obvious?

Element (C) is where a competent invalidity challenge either lives or dies.

• Under the 2009-08-28 date: encorafenib is the applicants' own novel species, first disclosed in WO 2011/025927 / US 8,501,758 (priority 2009-08-28). No pre-2009-08-28 reference I located discloses its structure. Substituting a newly invented, specifically selected species into a known and motivated combination is normally not obvious — an obviousness case cannot use the inventor's own not-yet-public compound as the missing element without an earlier genus reference from which the species could be selected. I did not locate a pre-August-2009 genus reference encompassing the encorafenib structure. If none exists, claim 1 survives on element (C) alone.
• Under a 2010 effective date: the analysis flips. WO 2011/025927 would still be the same-family self-disclosure (not art), so element (C) remains a gap — but the secondary combination art (US 2012/0015973, EP 2488033) closes elements (A)–(E) almost completely, and the case becomes a pure "single novel species + fully disclosed combination" argument, i.e. exactly the posture in which a §103 challenge is strongest.

Practical consequence: the outcome of any §103 attack on claim 1 is dominated by the priority-date question (was the Raf + MEK combination disclosed in 61/238,073?), which is a §112/§120 written-description question, not a prior-art question. That is the first thing I would brief.

6. Secondary grounds worth flagging

1. Obviousness-type double patenting. Claim 1 is a method of using encorafenib for melanoma; encorafenib as a compound is claimed in US 8,501,758 / RE 49,556 (same title, same eight inventors, same assignee). If the compound claims are not patentably distinct from and do not expire later than the method claims, ODP is available — subject to any terminal disclaimer. Notably, the Orange Book lists '229 (2030-08-27), US 8,501,758 (2030-08-27) and RE 49,556 ("Feb, 2030" per one table) on effectively the same date, which is consistent with a common priority chain and no truncating terminal disclaimer, but I could not confirm either way. Note the '464 patent is listed separately at 2031-07-04.
2. Real-world corroboration that some claims were conceded invalid. In Array BioPharma v. Alembic Pharmaceuticals, 1:22-cv-01277-GBW (D. Del.), a Joint Stipulated Order of Invalidity of Certain Claims of U.S. Patent Nos. 9,314,464, 9,850,229 and 10,005,761 was so-ordered on 2024-05-28. I do not know which claims, or on what ground (§102, §103 or §112). It is nonetheless the single most probative external signal on this patent's validity and should be pulled from PACER (D.I. 133/134) before any opinion is finalised.
3. Why the generics mostly don't attack it. Teva's ANDA 217635 (encorafenib capsules, 75 mg) filed paragraph III certifications to the '758, '575, '250, '464, '099, '100, '229, '230, '761 and '556 patents — i.e., Teva agreed to wait for expiry rather than challenge '229. That removes a large chunk of adversarial §103 testing, and explains why the inter partes record on '229's obviousness is thin.

7. Bottom line

• Claim 1's combination and patient-selection elements (A), (B), (D) are clearly obvious over WO 2008/120004 A1 alone or in view of WO 2009/018238, with routine BRAF V600E genotyping supplying (B). The motivation is express, in-field, mechanism-based and reinforced by a finite, enumerated MEK-inhibitor universe.
• Claims 2, 3 and the MEK-species-dependent claims are a fortiori obvious — US 2012/0015973 expressly teaches separate formulation, sequential administration, kits and melanoma, and every named MEK inhibitor was a known clinical compound.
• The whole case turns on element (C), the identity of encorafenib, and therefore on whether the '229 claims earn the 2009-08-28 priority date. If they do, and if no pre-August-2009 genus reference covering encorafenib exists, claim 1 is likely non-obvious notwithstanding the fully obvious combination. If they do not, the claims are in serious §103 jeopardy.
• Confidence: high on the prior-art references' content and dates (except WO 2009/018238's publication date, which I inferred); low-to-moderate on the priority-date question, which I could not resolve; high that the Google Patents prior-art pane was not present in the text supplied to me, so the reference set above is a reconstructed one rather than the patent's own face citations.